David Hung, President & CEO, Director at Medivation, holds 59.28M shares in Nuvation Bio (Ticker: NUVB), holds 23.41K shares in NovoCure (Ticker: NVCR), holds 0.00 shares in Sio Gene Therapies (Ticker: SIOX). Most recently, David Hung Bought ― shares of Nuvation Bio on Jun 18, 2025 for an estimated value of 890.00K.
David Hung latest transaction was an Informative Buy of $890.00K.
What was David Hung's most profitable transaction?
David Hung’s most profitable transaction was an Informative Buy of NUVB stock on April 8, 2025. The return on the trade was 38.50%.
What is David Hung's role in Medivation?
David Hung's role in Medivation is President & CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.